<DOC>
	<DOCNO>NCT02676336</DOCNO>
	<brief_summary>This randomize , double-blind , placebo control , multi-center study evaluate safety , tolerability potential effect dietary supplement Violet™ Iodine breast health woman cyclic breast discomfort tenderness eliminate evaluation effectiveness .</brief_summary>
	<brief_title>A Randomized Double-blind , Placebo Controlled , Multi-center Study Evaluate Safety , Tolerability Potential Effects Dietary Supplement Violet™ Molecular Iodine ( I2 ) Breast Health Women With Cyclic Breast Discomfort Tenderness</brief_title>
	<detailed_description />
	<mesh_term>Fibrocystic Breast Disease</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<mesh_term>Cadexomer iodine</mesh_term>
	<criteria>Healthy premenopausal female ≥ 18 year age BMI 20.0 29.9 kg/m2 ( ± 1 kg/m2 ) Females childbearing potential must agree use reliable consistent method birth control Investigator 's opinion , exclude depot contraceptive Explanon , negative urine pregnancy test result . Hormonal contraceptives oral contraceptive , birth control patch ( Ortho Evra ) , vaginal contraceptive ring ( NuvaRing ) acceptable long subject stable dose agrees change study period No apparent health condition investigator 's opinion would interfere study participation , compliance interpretation endpoint would best interest subject Moderate severe cyclic breast discomfort least 4 day per month ( discomfort ≥4 010 scale ) No know medical psychological condition investigator 's opinion could interfere study participation Agrees comply study related procedure visit include access smartphone ( Android iOS ) ability enter daily diary information via smart phone app Capable read understand study related material ( English French ) give voluntary , write , inform consent participate study Women pregnant , breast feeding , plan become pregnant course trial Perimenopausal irregular menstrual cycle Women oophorectomy Known thyroid condition currently take thyroid medication Prior bariatric surgery intervention medication might affect gastric pH Use iodine supplementation , Tamoxifen , Lupron , Danazol , last 6 month Clinically significant abnormal laboratory result Screening Breast implant surgery fully heal ongoing problem associate implant ( i.e . seroma , infection etc . ) Planned elective surgery occur participation study Known allergy sensitivity study product ingredient ( e.g . Iodine ) History alcohol drug abuse within past year Use medicinal marijuana within past year Participation clinical research trial within 30 day prior randomization plan participate study next 11 month Individuals cognitively impair and/or unable give inform consent Any condition Investigator 's opinion may adversely affect subject 's ability complete study measure , may confound interpretation study outcome measure ( another condition ) may pose significant risk subject</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>FBC</keyword>
	<keyword>cyclic mastalgia</keyword>
	<keyword>breast discomfort</keyword>
</DOC>